Management of Primary Ovarian Insufficiency Symptoms in Survivors of Childhood and Adolescent Cancer

Emma Gargus, BS; Rebecca Deans, MBBS, M Med; Antoinette Anazodo, MD; and Teresa K. Woodruff, PhD

Abstract
Cancer treatments can damage the ovaries, causing primary ovarian insufficiency (POI), a condition associated with numerous sequelae that impact long-term quality of life. This article systematically reviews the literature on the prevalence, surveillance, and treatment of POI in survivors of pediatric and adolescent and young adult (AYA) cancers. A systematic review of the literature was conducted in January 2018 through a search of Medline, Embase, Web of Science, and SCOPUS, alongside the screening of relevant reference lists. An initial search identified 746 potentially relevant studies. A total of 36 studies were included in the final review. Studies were categorized into one of the following categories: incidence/prevalence of POI, measurement of ovarian reserve, and other. Depending on patient characteristics, cancer diagnosis, and treatment, the prevalence of POI ranged from 2.1% to 82.2%. Risk factors for POI included exposure to alkylating agents and abdominal/pelvic radiation. POI may be associated with a number of complications, including low bone mineral density and poor cardiovascular health. Radiotherapy and chemotherapy are known to cause gonadal damage in female survivors of pediatric and AYA cancers. Acute or chronic effects depend on the dose of treatment, age of the individual, radiotherapy field, and ovarian reserve of the individual. Some women experience short-term loss of reproductive function and then may resume menstrual cycles, months or even years later. Although protecting fertility through banking of mature eggs, embryos, and tissue samples has become standard of care, additional steps need to be taken to ensure that patients have adequate hormone levels to maintain whole-body health, including life expectancy, bone health, cardiovascular health, quality of life, sexual and genitourinary function, and neurologic function. Surveillance and management of each of these comorbidities is critically important to survivor health.

J Natl Compr Canc Netw 2018;16(9):1137–1149
doi: 10.6004/jnccn.2018.7023

Modern cancer treatment regimens are highly effective, with up to 88.8% of patients with cancer aged <45 years surviving 5 years after diagnosis. With this success comes the need to think beyond life-and-death decision-making and toward long-term quality-of-life (QoL) considerations. Fertility-sparing options are available to many patients, and whether patients opt for these interventions depends on their family planning expectations. Survivors who are not provided with fertility options experience anxiety, which can be a comorbidity in its own right. Beyond fertility, patients with cancer also risk loss of endocrine function, leading to primary ovarian insufficiency (POI), a syndrome characterized by amenorrhea, sex hormone deficiency, and elevated serum follicle-stimulating hormone (FSH) levels on at least 2 occasions, tested at least 1 month apart in women aged <40 years. The cessation of episodic endocrine hormones may result in menopausal symptoms, such as hot flashes, vaginal dryness, and sexual dysfunction, as well as increased morbidity associated with a reduction of any products discussed in this article or their competitors.

This work was supported by the NIH National Center for Translational Research in Reproduction and Infertility (NCTRI) Center for Reproductive Health After Disease (PP0HD076188).

Correspondence: Teresa K. Woodruff, PhD, Northwestern University, 303 East Superior Street, Room 10-121, Chicago, IL 60411. Email: tkw@northwestern.edu
in endogenous estrogen, including bone mineral density (BMD) and cardiovascular changes. Thus, surveillance of the endocrine health of adolescent and young adult (AYA) cancer survivors is critical to their overall health.

This article systematically reviews the literature on prevalence and management of POI in survivors of pediatric and AYA cancers (aged 0–24 years). All peer-reviewed literature and qualitative and quantitative data reporting on prevalence, surveillance, and management of POI-related symptoms in cancer survivors are examined. To gain a full understanding of short-term and long-term treatment effects, data were not restricted by time from diagnosis. This inclusive approach allowed for the identification of POI symptoms that may emerge late after diagnosis and treatment. Thus, this review will help determine the scope of POI-related symptoms and their management at various time points throughout the cancer journey for pediatric and AYA cancer survivors.

Methods

Inclusion Criteria and Search

This systematic review considered all studies that discussed prevalence and management of sequelae related to POI in female survivors of pediatric and AYA cancers. We excluded studies that focused specifically on fertility or family planning. To meet inclusion criteria, patient age needed to be within the range of 0 to 24 years or have a mean sample age <25 years. Studies that focused on symptoms of POI during or after cancer treatment were included. Studies needed to be in English, published in a peer-reviewed journal, and of sound quality, as assessed using a validated quality assessment tool.10 No publication date restrictions were imposed.

A comprehensive literature search was performed in January 2018, with suitable studies identified through the electronic databases Medline, Embase, PsycInfo, Web of Science, and Scopus, alongside the screening of reference lists. Search terms were tailored to individual databases in order to map terms to database subject headings and take an inclusive approach (Table 1). The search across electronic databases and reference lists identified 746 potentially relevant studies after the deletion of duplicates. All titles and abstracts were screened by a single reviewer, who then assessed the full text of the remaining 150 studies to determine eligibility for inclusion. A total of 36 studies remained eligible for further analysis (Figure 1).

Quality Analysis and Extraction

The quality of the final studies was assessed using the Mixed Methods Appraisal Tool (MMAT).10 Scores on the MMAT vary from 25% (1 criterion met) to 100% (all criteria met). Quality was assessed against criteria related to either qualitative or quantitative enquiry. All 36 final studies were of sound quality (75%–100%) and were then analyzed for data by one reviewer. Data regarding sample size, patient characteristics (age, sex, cancer diagnosis, treatment), and descriptions and details of POI-related sequelae were extracted from each paper.

Table 1. Search Terms

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Primary Ovarian Insufficiency</th>
<th>Fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Menopause] or [menopause, premature] or [primary ovarian insufficiency]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Records identified through database search (n=84)</th>
<th>Additional records identified through other sources (n=92)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duplicates removed (n=240)</td>
<td></td>
</tr>
<tr>
<td>Records screened (n=746)</td>
<td>Records excluded (n=596)</td>
</tr>
<tr>
<td>Full-text articles assessed for eligibility (n=150)</td>
<td>Full-text articles excluded (n=114)</td>
</tr>
<tr>
<td>Aged &gt;24 y (n=36)</td>
<td>Fertility (n=6)</td>
</tr>
<tr>
<td>Case study n&lt;10 (n=10)</td>
<td>Conference (n=5)</td>
</tr>
<tr>
<td>Review/Editorial/Position statement (n=37)</td>
<td>Not cancer (n=5)</td>
</tr>
<tr>
<td>Not clinical (n=15)</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Flowchart of inclusion/exclusion process. Abbreviation: POI, primary ovarian insufficiency.
Ovarian Insufficiency in Cancer Survivors

Results

Study Characteristics

Tables 2 through 4 reflect the key features of each study. Table 2 includes the 17 studies that report the prevalence of POI in female survivors of pediatric and AYA cancers; Table 3 summarizes the data from 11 studies related to measurement of ovarian reserve; and Table 4 lists the remaining studies identified in this literature review. The number of subjects in Tables 2 through 4 reflects only the female cancer survivors in each study; some of the studies included male survivors and/or healthy controls, but these numbers are not reflected. Studies were conducted across 9 countries; the sample size range varied from 15 to 3,749 participants. Among the papers, 3 reported on acute lymphoblastic leukemia only, and 1 reported only on Hodgkin lymphoma, whereas the other studies reported on a range of cancer diagnoses; 7 studies did not report the specific cancer diagnoses.

Prevalence of and Risk Factors for POI in Survivors

Depending on patient factors, cancer diagnosis, and treatment exposures, the prevalence of POI in survivors of pediatric and AYA cancer ranged from 2.1% to 82.2% (Table 2). A recent report from the St. Jude Lifetime Cohort reported the prevalence of POI to be 10.9%. In this study, POI status was determined with hormone measurements (estradiol level <17 pg/mL and FSH level >30 IU/L before age 40 years), and therefore provides a more accurate figure for POI prevalence than previous studies that relied on self-report of menopausal status, in which true rates of POI can be obscured by factors such as use of combined oral contraceptive pills (COCPs). Multiple studies in different cohorts have reported the following risk factors for POI: cancer diagnosis after puberty, alkylating agents, especially busulfan, procarbazine, and cyclophosphamide; abdominal/pelvic radiation; and diagnosis of Hodgkin lymphoma. Given that these studies were performed in cohorts treated >20 years ago (before risk-adapted protocols and new, potentially gonadotoxic agents, such as tyrosine kinase inhibitors and PD-L1 inhibitors), it is difficult to predict how the prevalence of POI will compare in today’s and tomorrow’s survivors of childhood cancer.

Management of Perimenopause and Menopause in Survivors

POI results in the cessation of menses and postmenopausal levels of sex hormones and gonadotropins. Regardless of the cause (spontaneous menopause vs treatment-induced POI), menopause is characterized by a constellation of symptoms, including vasomotor symptoms (hot flashes and night sweats), osteoporosis with associated fracture risk, and vaginal dryness and dyspareunia. In addition to these symptoms, women experiencing perimenopause and menopause often complain of anxiety, depression, irritability, loss of libido, palpitations, skin dryness, and fatigue, although it is debated whether these symptoms can be attributed to menopause. Importantly, many of these menopause symptoms mirror common chemotherapy and radiation side effects. It may be easy to dismiss these symptoms as side effects, but they may be a harbinger of ovarian damage. Careful history taking and physical examination, supplemented with appropriate laboratory tests, may help patients have more realistic expectations regarding their ovarian function and their risks of morbidity/mortality. For women, there is social value in ovarian function and fertility, such that ovarian failure and menopause may impose psychosocial burden. Regardless, it is important for providers to recognize the distress these symptoms cause patients and manage the symptoms using a combination of pharmacologic treatments, behavioral interventions, and communication. The following sections review recommendations for comprehensive perimenopause/menopause (or POI) care in young female cancer survivors.

Perimenopause: Perimenopause is the transition between regular cycling and menopause, often characterized by heavy, irregular vaginal bleeding and irregular ovulations, which can increase the risk of unintended pregnancy. Contraception counseling is necessary for all women of childbearing age, even those who have POI. Iatrogenic POI may be transient, and hence an instance of ovarian dysfunction does not assure complete and permanent infertility. For example, recovery of ovarian function was observed in 38.5% of female survivors of primary central nervous system embryonal tumors treated with craniospinal radiation followed by adjuvant cyclophosphamide and stem cell rescue. Many options for contraception are available, including hormonal and nonhormonal methods, with the latter more appropriate for survivors of...
### Table 2. POI Prevalence Data Extracted by Study

<table>
<thead>
<tr>
<th>Study Details</th>
<th>Age, y</th>
<th>Cancer</th>
<th>Treatment</th>
<th>Method</th>
<th>Prevalence (%)</th>
<th>Risk Factors</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Livey et al, 1990 (UK)</td>
<td>Median age at diagnosis, 13.0 (range, 9.0–15.2)</td>
<td>32</td>
<td>HL</td>
<td>ChVPP</td>
<td>31.25%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Byrne et al, 1992 (US)</td>
<td>Median age at diagnosis, 13.9 (range, 11.5–21.1)</td>
<td>21</td>
<td>Various</td>
<td>RT and/or chemo</td>
<td>Self-report/questionnaire</td>
<td>42.0% (by age 31 y)</td>
<td>Cancer diagnosis after age 12 years (RR, 2.32; 95% CI, 1.63–3.29) RT alone (RR, 3.7) Alkylating agents alone (RR, 9.2) Both RT and alkylating agents (RR, 27.39; 95% CI, 2.67–31.49)</td>
</tr>
<tr>
<td>Mackie et al, 1996 (UK)</td>
<td>Median age at diagnosis, 13.9 (range, 11.5–21.1)</td>
<td>719</td>
<td>60.1% solid tumors; 39.9% hematologic</td>
<td>Chemo, surgery, and/or RT</td>
<td>Self-report/questionnaire</td>
<td>8.8%</td>
<td>Alkylating agents and abdominal/pelvic RT (RR, 2.58; 95% CI, 1.14–5.80)</td>
</tr>
<tr>
<td>Teinturier et al, 1998 (France)</td>
<td>Median age at diagnosis, 13.9 (range, 11.5–21.1)</td>
<td>2,819</td>
<td>45% solid tumors; 55% hematologic</td>
<td>10% surgery only; 10% chemo only; &lt;1% RT only; 17% chemo + RT; 20% surgery + chemo; 8% surgery + RT; 33% surgery + RT + chemo; 1% stem cell transplant</td>
<td>Self-report/questionnaire</td>
<td>15% (RR, 1.05; 95% CI, 1.04–1.07 vs siblings); 8% nonsurgical POI</td>
<td>Older age at diagnosis and follow-up</td>
</tr>
<tr>
<td>Chiarelli et al, 1999 (Canada)</td>
<td>Median age at diagnosis, 13.9 (range, 11.5–21.1)</td>
<td>2,819</td>
<td>Not described</td>
<td>Not described</td>
<td>Self-report/questionnaire</td>
<td>8%</td>
<td>Attained age Exposure to increasing doses of radiation to the ovaries</td>
</tr>
<tr>
<td>Green et al, 2009 (US, Canada)</td>
<td>Median age at diagnosis, 13.9 (range, 11.5–21.1)</td>
<td>706</td>
<td>85% solid tumors; 15% hematologic</td>
<td>9% no chemo or RT; 29.5% chemo; 13% RT; 48.5% chemo + RT</td>
<td>Self-report/questionnaire</td>
<td>2.1%</td>
<td>Alkylating agents (RR, 9; 95% CI, 2.7–18) Radiotherapy to ovaries Procarbazine dose Cyclophosphamide dose</td>
</tr>
<tr>
<td>Thomas-Teinturier et al, 2013 (France)</td>
<td>Median age at diagnosis, 13.9 (range, 11.5–21.1)</td>
<td>21</td>
<td>Various</td>
<td>RT and/or chemo</td>
<td>Self-report/questionnaire</td>
<td>42.0% (by age 31 y)</td>
<td>Cancer diagnosis after age 12 years (RR, 2.32; 95% CI, 1.63–3.29) RT alone (RR, 3.7) Alkylating agents alone (RR, 9.2) Both RT and alkylating agents (RR, 27.39; 95% CI, 2.67–31.49)</td>
</tr>
</tbody>
</table>

Abbreviations: aHSCT, autologous hematopoietic stem cell transplantation; ALL, acute lymphoblastic leukemia; BMT, bone marrow transplant; CED, cyclophosphamide equivalent dose; chemo, chemotherapy; ChIVPP, chlorambucil/vinblastine/procarbazine/prednisolone; CNS, central nervous system; HL, Hodgkin lymphoma; HR, hazard ratio; HRT, hormone replacement therapy; MMAT, Mixed Methods Appraisal Tool; POI, primary ovarian insufficiency; RR, relative risk; RT, radiotherapy.

*The number of patients reflects only the female cancer survivors in each study; some of these studies included male survivors and/or healthy controls, but these numbers are not reflected.*

(continued on next page)
Ovarian Insufficiency in Cancer Survivors

Risk Factors

The number of patients reflects only the female cancer survivors in each study; some of these studies included male survivors and/or healthy controls, but these numbers are not reflected.

Table 2. POI Prevalence Data Extracted by Study (cont.)

<table>
<thead>
<tr>
<th>Study Details</th>
<th>Age, y</th>
<th>n</th>
<th>Cancer</th>
<th>Treatment</th>
<th>Method</th>
<th>Prevalence</th>
<th>Risk Factors</th>
<th>Notes</th>
<th>MMAT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hudson et al.a, 2013 (US)</td>
<td>Median age at diagnosis, 7.5 (range, 0.0–24.0); median age at study, 33.8 (range, 18.0–60.0)</td>
<td>880</td>
<td>35.4% solid tumors; 64.6% hematologic</td>
<td>Chemo, RT, and/or surgery</td>
<td>Hormone measurement and self-report/questionnaire</td>
<td>31.9%</td>
<td>This study demonstrated that a systematic risk-based medical assessment identified a substantial number of previously undiagnosed problems</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>Raciborska et al., 2015 (Poland)</td>
<td>Median age at diagnosis, 12.2 (range, 2.8–18.9); median age at study, 16.3 (range, 10.5–31.6)</td>
<td>27</td>
<td>Ewing sarcoma</td>
<td>4 groups: chemo without pelvic RT, chemo with pelvic RT, chemo and autologous hematopoietic stem cell rescue without pelvic RT, and chemo + pelvic RT + aHSCT</td>
<td>Hormone measurement</td>
<td>67%</td>
<td>Pelvic RT (RR, 3.3; 95% CI, 1.1–13.6)</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>DeWire et al., 2015 (US)</td>
<td>At diagnosis, age range: 3–21</td>
<td>30</td>
<td>Primary CNS embryonal tumors</td>
<td>Craniospinal RT followed by adjuvant cyclophosphamide and stem cell rescue</td>
<td>Hormone measurement</td>
<td>82.8%</td>
<td>Recovery of ovarian function seen in 38.5%</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Salih et al., 2015 (US)</td>
<td>Median age at diagnosis, 7 (range, 0–20); age at last follow-up, 14.0 (range, 2–34)</td>
<td>222</td>
<td>Various (25% ALL)</td>
<td>Chemo, RT, BMT, or combination</td>
<td>Hormone measurement</td>
<td>14%</td>
<td></td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>Eichuri et al., 2016 (US)</td>
<td>Mean age at diagnosis, 6.4 (range, 1–18); mean age at study, 14.5 (range, 10–21)</td>
<td>49</td>
<td>47% solid tumors; 53% hematologic</td>
<td>Alkylating agent/heavy metal chemo and/or radiation exposure to the ovaries</td>
<td>Hormone measurement</td>
<td>10.2%</td>
<td></td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>Wilson et al., 2016 (US)</td>
<td>Median age at diagnosis, 5.0 (range, 0.2–19.5); median age at study, 31.3 (range, 18.4–59.7)</td>
<td>436</td>
<td>Various</td>
<td>RT, methotrexate, cyclophosphamide, glucocorticoids</td>
<td>Hormone measurement</td>
<td>11%</td>
<td>Of women with POI, 21.3% were taking HRT</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>Chemaitilly et al., 2017 (US)</td>
<td>Median age at diagnosis, 8.10; age at study, 31.7 (range, 19.0–60.6)</td>
<td>921</td>
<td>38.9% solid tumors; 61.1% hematologic</td>
<td>13.3% pelvic RT; 58.8% alkylating agents</td>
<td>Hormone measurement</td>
<td>10.9%</td>
<td>Ovarian RT at any dose (HR, 71.70; 95% CI, 16.50–311.58)</td>
<td>Only 31% of patients with POI received HRT</td>
<td>100</td>
</tr>
</tbody>
</table>

Abbreviations: aHSCT, autologous hematopoietic stem cell transplantation; ALL, acute lymphoblastic leukemia; BMT, bone marrow transplant; CED, cyclophosphamide equivalent dose; chemo, chemotherapy; ChIVPP, chlorambucil/etoposide/procarbazine/prednisolone; CNS, central nervous system; HL, Hodgkin lymphoma; HR, hazard ratio; HRT, hormone replacement therapy; MMAT, Mixed Methods Appraisal Tool; POI, primary ovarian insufficiency, RR, relative risk; RT, radiotherapy.

The number of patients reflects only the female cancer survivors in each study; some of these studies included male survivors and/or healthy controls, but these numbers are not reflected.

hormone-dependent cancers. To set realistic expectations, providers should clearly explain that future ovarian function and fertility after cancer treatments are uncertain and that fertility preservation should be pursued as early as possible, ideally before cancer treatment, if it is desired.

Various methods have been used to determine ovarian reserve in female cancer survivors, including serum anti-Müllerian hormone (AMH), antral follicle count (AFC), and ovarian volume or surface area (Table 3). Nielsen et al.91 found that serum AMH level and AFC were highly correlated (r=0.83; P<.001) in a study of 71 Danish survivors of childhood cancer. Determination of AFC and ovarian volume or surface area require the use of transvaginal sonography and are thus invasive. Measurement of AMH level, although controversial, is a less invasive test. Moreover, in a prospective study of the effect of cancer treatment on ovarian reserve, Brougham et al.10 assessed AMH levels at various points throughout treatment in a cohort of 22 patients with cancer, ranging from 0.3 to 15 years of age, and showed that AMH could be detected at all ages. Although still controversial, mea-
# Table 3. Ovarian Reserve Data Extracted by Study

<table>
<thead>
<tr>
<th>Study Details</th>
<th>Age, y</th>
<th>n</th>
<th>Cancer</th>
<th>Treatment</th>
<th>Method</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bath et al,10 2003 (UK)</td>
<td>Mean age at diagnosis, 6.3 (range, 0.6–13.8); median age at study, 25.3 (range, 19.1–32.7)</td>
<td>21 48% solid tumors; 52% hematologic</td>
<td>100% chemo; 48% RT</td>
<td>Hormone measurement Transvaginal ultrasound</td>
<td>Serum FSH levels were elevated (7.5 ± 1.4 vs 4.2 ± 0.3 IU/L; P&lt;.02) and serum AMH levels were lower (13.0 ± 3.0 vs 21.0 ± 3.4 pmol/L; P&lt;.05) in survivors with regular cycles vs controls</td>
<td></td>
</tr>
<tr>
<td>Larsen et al,10 2003 (Denmark)</td>
<td>Median age at diagnosis, 5.8 (range, 0.1–16.8); median age at study, 25.5 (range, 17.0–47.4)</td>
<td>34 59% solid tumors; 42% hematologic</td>
<td>93% chemo (57% received alkylating agents); 36%; RT; 63% chemo + RT</td>
<td>Hormone measurement Transvaginal ultrasound</td>
<td>Survivors had smaller ovarian volume (4.9 vs 6.8 cm³; P&lt;.01), a lower AFC (4.5 vs 8 per ovary; P&lt;.01), and a lower total number of follicles per ovary (8 vs 11; P&lt;.01) Cycle length in survivors was shorter vs control group (28.3 vs 31.0 days; P&lt;.05) Even survivors with regular menstrual cycles and basal FSH &lt;10 IU/L seem to have a DOR by AFC and ovarian volume</td>
<td></td>
</tr>
<tr>
<td>Lie Fong et al,10 2009 (the Netherlands)</td>
<td>Median age at treatment, 4.4 (range, 0.3–15)</td>
<td>22 Various</td>
<td>Chemo + RT</td>
<td>Hormone measurement Serial hormone measurements</td>
<td>Pretreatment AMH was detectable across the age range studied AMH decreased progressively during chemo (P&lt;.00001) in both pre- and postpubertal girls and became undetectable in 50% of patients AMH recovered in the low/medium-risk group but not in the high-risk group even at 3 years of follow-up</td>
<td></td>
</tr>
<tr>
<td>Nielsen et al,10 2013 (Denmark)</td>
<td>Age at diagnosis, &lt;15</td>
<td>71 42.3% solid tumors; 57.7% hematologic</td>
<td>Chemo + RT</td>
<td>Hormone measurement Transvaginal ultrasound</td>
<td>Compared with controls, survivors had lower AFC (median, 15 vs 18; P&lt;.047) but no significant difference in AMH (median, 13.0 vs 17.8 pmol/L) AMH concentration and AFC were highly correlated (r=0.83; P&lt;.001) AFC in survivors with regular menses is significantly lower than age-matched controls AMH was significantly lower in the high-risk treatment group vs both the control group and the low/medium-risk treatment group</td>
<td></td>
</tr>
<tr>
<td>Krawczuk-Rybak et al,12 2013 (Poland)</td>
<td>Mean age at diagnosis, 10.5 (range, 0.9–17.6); mean age at study, 18.78 ± 4.98</td>
<td>83 59% solid tumors; 41% hematologic</td>
<td>Chemo + RT</td>
<td>Hormone measurement</td>
<td>AMH was low in all 83 female survivors regardless of theoretical risk of treatment AMH was lowest in women who had received BMT or had a diagnosis of HL FSH was only elevated in the high-risk treatment group</td>
<td></td>
</tr>
<tr>
<td>Krawczuk-Rybak et al,13 2013 (Poland)</td>
<td>High-risk group, 14 ± 3.4; low/medium-risk group, 7.56 ± 4.73</td>
<td>33 Various</td>
<td>Chemo + RT</td>
<td>Hormone measurement</td>
<td>AMH was significantly lower in the high-risk group vs both the healthy control group and the low/medium-risk group 4–6 years later when AMH levels were measured for the second time, they were significantly lower in the high-risk group vs the previous measurement</td>
<td></td>
</tr>
<tr>
<td>Charpentier et al,14 2014 (Canada)</td>
<td>Median age at diagnosis, 11.9 (range, 1.8–17.3); median age at study, 23.3 (range, 18.2–34.2)</td>
<td>66 9.1% solid tumors; 90.9% hematologic</td>
<td>100% chemo; 56.1% RT (none received pelvic); 9.1% surgery</td>
<td>Hormone measurement</td>
<td>34.8% had low AMH (&lt;14.3 pmol/L) Sarcoma survivors had significantly lower AMH vs ALL survivors Low AMH was associated with higher CED (especially procarbazine dose), older age at diagnosis, and use of OCPs</td>
<td></td>
</tr>
<tr>
<td>Lunsford et al,15 2014 (US)</td>
<td>Mean age at diagnosis, 6.3 (range, 0.5–17.3); mean age at study, 13.9 (range, 9–25)</td>
<td>53 45% solid tumors; 55% hematologic</td>
<td>100% chemo; 50% RT</td>
<td>Hormone measurement OSA</td>
<td>(continued on next page)</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** AFC, antral follicle count; ALL, acute lymphoblastic leukemia; AMH, anti-Müllerian hormone; BMT, bone marrow transplant; CED, cyclophosphamide equivalent dose; chemo, chemotherapy; CDDP, combined oral contraceptive pills; DOR, diminished ovarian reserve; FSH, follicle-stimulating hormone; HL, Hodgkin lymphoma; MMAT, Mixed Methods Appraisal Tool; MOPP, mechlorethamine/vindesine/procarbazine/prednisone; OCPs, oral contraceptive pills; OSA, ovarian surface area; POI, primary ovarian insufficiency; RT, radiotherapy; TBI, total body irradiation.

1 The number of patients reflects only the female cancer survivors in each study; some of these studies included male survivors and/or healthy controls, but these numbers are not reflected.
Ovarian Insufficiency in Cancer Survivors

Does POI Lead to Increased Morbidity/Mortality?
POI affects not only fertility, but a broad range of organ systems, including cardiovascular, musculoskeletal, and neurologic systems. The best evidence for long-term effects of POI is from the Mayo Clinic Cohort Study of Oophorectomy and Aging-1. In this cohort, women who had bilateral oophorectomy before age 45 years had increased mortality compared with age-matched control women (hazard ratio [HR], 1.67; 95% CI, 1.16–2.40; \( P = .006 \)).\(^\text{50} \) Primary causes of death were cardiovascular disease and osteoporotic fracture, and the study also reported cognitive impairment, dementia, Parkinsonism, sexual dysfunction, and reduced psychological well-being. Other large observational studies have also investigated morbidity/mortality in women with iatrogenic POI caused by surgical removal of the ovaries. The Nurses’ Health Study found increased mortality (HR, 1.12; 95% CI, 1.03–1.21) among women who underwent total abdominal hysterectomy (TAH) with bilateral oophorectomy (TAHBSO) compared with those who underwent TAH alone, with 24 years of follow-up.\(^\text{51} \) The Women’s Health Initiative (WHI) Observational Study found no difference in mortality between TAHBSO and TAH, but had <8 years of follow-up.\(^\text{52} \) Several epidemiologic studies also support the notion that POI is associated with increased mortality. In a Dutch cohort of 12,000 women followed over 17 years, life expectancy of women with POI was 2 years less than that of controls.\(^\text{53} \) Similar results have been seen in non-Caucasian populations, including Japanese,\(^\text{54} \) Korean,\(^\text{55} \) and Chinese women.\(^\text{56} \)

Influence of Estrogen Replacement on Mortality After POI
No long-term prospective studies have examined the safety and efficacy of estrogen replacement therapy in terms of mortality in patients with POI.\(^\text{57} \) Evidence regarding the use of hormone replacement therapy (HRT) in survivors of childhood cancer is even more limited. However, evidence suggests that women who do not receive HRT have increased mortality compared with those who receive treatment. Shuster et al.\(^\text{58} \) reported increased mortality in women experiencing menopause before age 45 years who did not receive estrogen replacement. The WHI randomized controlled trials of HRT versus placebo did not show a protective effect of HRT within 10

<table>
<thead>
<tr>
<th>Study Details</th>
<th>Age, y</th>
<th>Cancer</th>
<th>Treatment</th>
<th>Method</th>
<th>Results</th>
<th>MMAT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas-Teinturier et al.(^\text{59} ) 2015 (France)</td>
<td>145</td>
<td>Various (25% ALL)</td>
<td>Chemo, RT, BMT, or combination</td>
<td>Hormone measurement</td>
<td>Survivors had lower OSA (3.5 vs 4.4 cm(^{2}); ( P = .0004 )) and AMH levels (10.7 vs 22 pmol/L; ( P = .003 )) vs controls, but AFC was not different (12 vs 11; ( P = .8 )). OSA, AMH, and AFC were lower in patients who received high-dose vs conventional-dose alkylating agents (( P = .01 ) for OSA; ( P = .002 ) for AMH; ( P = .0001 ) for AFC).</td>
<td>100</td>
</tr>
<tr>
<td>Salih et al.(^\text{50} ) 2015 (US)</td>
<td>222</td>
<td>Various (25% ALL)</td>
<td>Chemo, RT, BMT, or combination</td>
<td>Hormone measurement</td>
<td>69% had normal ovarian reserve (FSH &lt;10 IU/L), 17% had DOR (FSH, 10–40 IU/L), 14% had POI (FSH &gt;40 IU/L)</td>
<td>75</td>
</tr>
</tbody>
</table>

Abbreviations: AFC, antral follicle count; ALL, acute lymphoblastic leukemia; AMH, anti-Müllerian hormone; BMT, bone marrow transplant; CED, cyclophosphamide equivalent dose; chemo, chemotherapy; COCPs, combined oral contraceptive pills; DOR, diminished ovarian reserve; FSH, follicle-stimulating hormone; HL, Hodgkin lymphoma; MMAT, Mixed Methods Appraisal Tool; MOPP, mechlorethamine/vincristine/procarbazine/prednisone; OCPs, oral contraceptive pills; OSA, ovarian surface area; POI, primary ovarian insufficiency; RT, radiotherapy; TAH/TAHBSO, total abdominal hysterectomy (with or without bilateral oophorectomy); \( P = .8 \)) vs controls, but AFC was not different (12 vs 11; \( P = .8 \)). OSA, AMH, and AFC were lower in patients who received high-dose vs conventional-dose alkylating agents (\( P = .01 \) for OSA; \( P = .002 \) for AMH; \( P = .0001 \) for AFC). HL survivors had the greatest reduction in ovarian parameters, and procarbazine (not cyclophosphamide or ifosfamide) dose was associated with reduced OSA, AFC, and AMH, and higher FSH; however, the individual impacts of procarbazine and HL on ovarian reserve could not be dissociated. AFC was correlated with AMH and, to a lesser extent, OSA.

The amount of serum AMH levels may be the most appropriate test for some patients and can help guide fertility counseling and decision-making. AMH level correlates with the degree of ovarian damage after cancer treatment\(^\text{60} \) and measures ovarian reserve, although it does not necessarily predict the likelihood of future live births.\(^\text{49} \)

Table 3. Ovarian Reserve Data Extracted by Study (cont.)
years of menopause against cardiovascular disease or death (HR, 0.76; 95% CI, 0.50–1.16; absolute excess risk: 6/10,000 woman-years). Caution must be exercised regarding the timing of initiation of estrogen replacement, because the protective effects are considered to be optimal with its introduction in relatively atheroma-free vessels compared with atheromatous vessels, in which it is considered to have a prothrombotic effect.

**Bone Health and Chemotherapy-Related Changes in BMD**

We have long known the relationship between estrogen and bone health. Estrogen deficiency results in increased bone remodeling, mediated by increased activity of osteoclasts relative to osteoblasts, resulting in more bone resorption than formation. There is a net bone loss of 2% to 3% per year after menopause. Bone remodeling is reversible in the short-term, but with time, high osteoclast activity can result in permanent loss of bony microarchitecture, especially in trabecular bone.

We know that women with POI have reduced BMD related to the presence, degree, and duration of their estrogen deficiency. This relationship holds for many causes of POI, including cancer-related POI. A recent study of 442 women with idiopathic POI reported a 2% to 3% lower BMD at the lumbar spine and hip compared to women without menopause.

### Table 4. Data From Remaining Studies

<table>
<thead>
<tr>
<th>Study Details</th>
<th>Age, y</th>
<th>n</th>
<th>Cancer</th>
<th>Treatment</th>
<th>Results</th>
<th>MMAT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wilson et al, 2016 (US)</td>
<td>Median age at diagnosis, 6.9 (range, 0–21); median age at study, 36.2 (range, 21.2–58.8)</td>
<td>3,749</td>
<td>Various</td>
<td>Alkylating agents, MTX, glucocorticoids, cranial irradiation, pelvic RT</td>
<td>Prevalence of fractures among female survivors and sibling controls was comparable. Risk factors for fractures in female survivors were increasing age at follow-up, white race, MTX treatment, and balance difficulties.</td>
<td>100</td>
</tr>
<tr>
<td>Gurney et al, 2003 (US)</td>
<td>Age at diagnosis &lt;20</td>
<td>734</td>
<td>Brain tumors</td>
<td>25.8% surgery only; 42.4% surgery + RT; 27.8% surgery + RT + chemo; 4.0% other treatments</td>
<td>43% reported ≥1 endocrine condition RR for osteoporosis, 24.7 (95% CI, 9.9–61.4)</td>
<td>75</td>
</tr>
<tr>
<td>Ness et al, 2013 (US)</td>
<td>Mean age at study, 33.6 ± 8.1</td>
<td>956</td>
<td>37.3% solid tumors; 2.7% hematologic</td>
<td>RT, chemo, surgery</td>
<td>Prevalence of prefrailty and frailty were 31.5% and 13.1%, respectively, among women; similar to rates seen in the population aged &gt;65 years. Increasing age and cranial RT were the only factors associated with frailty</td>
<td>75</td>
</tr>
<tr>
<td>Tomioka et al, 2017 (Japan)</td>
<td>Median age at diagnosis, 7 (range, birth–15); median age at study, 25 (range, 20–41)</td>
<td>49</td>
<td>30.6% solid tumors; 69.4% hematologic</td>
<td>65.2% RT (13 TBI, 8 cranial); 36.7% HSCT</td>
<td>40.8% experienced gonadal dysfunction 20.4% experienced endocrine dysfunction 8.2% experienced muscle/bone damage 6.1% experienced cardiovascular dysfunction 4.1% experienced neurocognitive dysfunction or mental problems</td>
<td>75</td>
</tr>
</tbody>
</table>

**Abbreviations:** ALL, acute lymphoblastic leukemia; BMD, bone mineral density; chemo, chemotherapy; HSCT, hematopoietic stem cell transplantation; MMAT, Mixed Methods Appraisal Tool; MTX, methotrexate; OR, odds ratio; POI, primary ovarian insufficiency; RR, relative risk; RT, radiotherapy; TBI, total body irradiation.

The number of patients reflects only the female cancer survivors in each study; some of these studies included male survivors and/or healthy controls, but these numbers are not reflected.
In addition to physical discomfort, β-decreases in BMD should prompt consideration of changes in treatment. Low BMD as assessed on dual-energy x-ray absorptiometry (DEXA) scans serves as a clinically convenient surrogate marker for fracture risk and treatment effects on bone health. Although BMD has been correlated with fracture risk in postmenopausal women, this relationship has not been definitively established in women with POI. It is critical to note the challenges in interpreting DEXA scans in the adolescent age group; namely because DEXA is not a volumetric measurement, it is necessary to adjust for short stature and delayed puberty by interpreting the values in the context of the patient’s height.

**Bone Health Interventions and Monitoring**

Studies of interventions to improve bone health have generally examined surrogate markers for fracture risk, such as DEXA scans. Lifestyle interventions, such as smoking cessation, regular weight-bearing exercise, increased intake of calcium and vitamin D, moderate alcohol consumption, and maintenance of a healthy body weight, are likely to improve BMD and therefore fracture risk in women with POI.\(^{40}\) Estrogen replacement has shown clear benefits for postmenopausal women in increasing BMD and reducing fracture risk. In women with POI, estrogen replacement improves BMD as assessed by DEXA, but there is insufficient evidence of its effect on fracture risk. COCPs are widely used to support bone health in women with POI, but a crossover randomized controlled trial showed that transdermal 17β-estradiol and micronised progesterone HRT, which provided physiologic levels of sex hormones, outperformed COCPs in terms of lumbar bone density, bone turnover markers, and bone formation markers, although the sample size was low.\(^{40}\) Currently, there are no trials on the uses of non-hormonal pharmacotherapies for women with POI, such as bisphosphonates, selective estrogen receptor modulators, or strontium/denosumab. Bisphosphonates are especially problematic for women desiring subsequent pregnancy. Regarding surveillance of bone health, guidelines from the Children’s Oncology Group recommend a baseline DEXA scan when survivors enter long-term follow-up (generally at 2 years after completion of therapy);\(^{69}\) no consensus exists on the optimal intervals for repeated screening, both in the cancer survivor population and in postmenopausal women.\(^{70}\) Scans should therefore be repeated as clinically indicated based on individual risk factors, such as exposure to glucocorticoids, cranial radiation, methotrexate, or hematopoetic stem cell transplantation, or if DEXA results would alter treatment.\(^{71}\) Decreases in BMD should prompt consideration of changes in treatment.

**Cardiovascular Risk and Monitoring**

**Cardiovascular Health**

Women with POI have increased risk of cardiovascular disease compared with age-matched controls,\(^{72}\) because decreased endogenous estrogen production leads to changes in lipid profiles that result in a more atherogenic milieu. In a study of 49 female cancer survivors in Japan, 6.1% experienced cardiovascular dysfunction.\(^{44}\) Of these women, 40.8% had undergone HRT. In a study of 18 women aged 19 to 39 years with POI, physiologic estrogen replacement with transdermal 17β-estradiol resulted in lower blood pressure, improved renal function, and decreased activation of the renin-angiotensin system.\(^{73}\) To date, there are no established guidelines for managing cardiovascular risk in women with POI, but this study demonstrates the protective effect of estrogen in maintaining cardiovascular health in young female cancer survivors. The importance of regular screening for cardiovascular risk factors should be emphasized, including monitoring of blood pressure, lipids, fasting glucose, and body mass index, and counseling for smoking cessation and maintaining a balanced diet and regular physical activity.

**Genitourinary Function**

Women with POI often experience vaginal dryness, causing dyspareunia, or discomfort with intercourse. Our systematic review did not uncover any studies related to genitourinary symptoms in survivors of pediatric and AYA cancers experiencing POI. We therefore searched the literature on breast cancer survivors, and found recent evidence showing that genitourinary symptoms are rarely assessed or treated in this population, revealing a missed opportunity to improve QoL.\(^{74}\) In addition to physical discomfort, hormonal changes in survivors with POI are also as-
sociated with alterations in libido and arousal. Libido may be affected by the emotional burden of disease and its ongoing sequelae. Patients may experience anxiety and depression, sleep disturbance, pain, loss of skin sensation, changes in body image or weight, and strained intimate partner relationships that may compromise sexual function.73 Interventions to address genitourinary function include systemic estrogen replacement, local vaginal estrogen replacement, and androgen replacement, and nonmedical strategies, including pelvic floor exercises, clitoral therapy devices, individual or couple’s therapy, and use of vaginal lubricants.76,77

**Neurolgic Function**

Evidence suggests that POI may be associated with impairments in neurologic function. Women with POI after hysterectomy and oophorectomy without estrogen replacement have shown an acute decline in verbal memory and increased risk of dementia and Parkinson disease.78,79 A systematic review showed that the relationship between neurologic function and iatrogenic POI after breast cancer treatment was inconclusive, partly because most studies did not consider menopausal status a potential contributor to neurologic dysfunction.80 A Japanese study of 49 fe-
male childhood cancer survivors reported that 4.1% experienced neurocognitive dysfunction.44 Further studies with larger sample sizes and more diverse patient populations are needed to establish the link between cancer-related POI and cognitive dysfunction.

It is possible that estrogen replacement may improve neurologic function in POI. Strong evidence suggests that estrogen exerts protective effects on the aging brain, but limited data show improvements in cognitive function with HRT,63 with some evidence suggesting that there is a “window of opportunity” for estrogen to exert its neuroprotective effects.81

**Vasomotor Symptoms**

Vasomotor symptoms, such as hot flashes and night sweats, are the most common and among the most burdensome menopause symptoms, affecting up to 80% of women.46 Hot flashes are a significant driver of decreased QoL in postmenopausal women and are also at least partially responsible for menopause-related sleep disturbance. Behavioral modifications, such as dressing in layers, keeping living spaces cool, and avoiding food triggers (alcohol and spicy foods), may help reduce the severity and frequency of hot flashes. Obesity is associated with more severe hot flashes, and therefore maintenance of a healthy weight is recommended to relieve vasomotor symptoms and for general health.

Stress reduction through yoga and meditation has also been shown to improve vasomotor symptoms.82 Although behavioral modifications carry little to no risk and may provide some symptom relief, pharmacologic treatments are also available. HRT remains the most effective treatment for vasomotor symptoms, although it may not be appropriate for all patients. There are absolute and relative contraindications to HRT, including significant cardiovascular risk factors and history of breast cancer. Children exposed to chest radiotherapy during cancer treatment are at an increased risk for developing breast cancer in adulthood. Among these patients, survivors treated with HRT for menopause at age <20 years had a lower breast cancer risk than premenopausal survivors (HR, 0.47; 95% CI, 0.23–0.94), indicating that exogenous hormones do not fully mirror the role of endogenous hormones in the development of breast cancer.83

Using shared decision-making, providers and patients should weigh individual risks and benefits when deciding whether to begin, continue, or discontinue HRT. If HRT is to be prescribed in a woman with an intact uterus, it should contain both estrogen and progesterone, because this can decrease the risk of endometrial hyperplasia and cancer. Even so, women should be screened regularly for irregular, heavy bleeding, which can indicate endometrial hyperplasia and cancer. As an added bonus, combined estrogen/progesterone therapy not only treats vasomotor symptoms but also serves as a contraceptive.47 For women without a uterus, estrogen can be given alone as HRT. In women for whom HRT is inappropriate or unacceptable and behavioral interventions do not provide sufficient symptom relief, nonhormonal pharmacologic options include serotonin reuptake inhibitors, norepinephrine reuptake inhibitors, gabapentin, and pregabalin.46

**Discussion**

The goal of this article was to systematically review the literature on surveillance and management of POI in young female cancer survivors. Because few of
these studies were found, the search was broadened to idiopathic POI, surgically induced early menopause, and management of menopause symptoms in adult cancer survivors, and results were extrapolated to the pediatric and AYA cancer population. Although these studies likely provide valuable information on the management of menopause symptoms, they do not take into account the additional burden of disease process and other comorbidities associated with treatment that are experienced by pediatric and AYA cancer survivors. The Children’s Oncology Group publishes Long-Term Follow-Up Guidelines, which recommend screening and management of specific conditions, such as POI or osteopenia, for survivors with exposures that place them at high-risk for these conditions. However, Hudson et al screened childhood cancer survivors based on their exposure risk and uncovered a substantial number of previously undiagnosed problems, indicating that systematic risk-based medical assessments are underused. Moreover, a recent study that examined the prevalence of endocrinopathies in the Childhood Cancer Survivor Study cohort showed that even survivors treated with “low-risk” therapies experience an increased risk for endocrine disorders compared with sibling controls. This observation highlights the need for long-term surveillance and individualized screening practices for all survivors of pediatric and AYA cancers regardless of predicted risk of treatment exposure.

Like all women, modifiable lifestyle factors likely contribute to symptom severity, and young female cancer survivors should be advised to adopt healthier habits. Additionally, psychological factors likely play a large role in QoL among young female cancer survivors. Women with cancer-related POI have higher levels of depression, higher perceived stress, and lower levels of self-esteem and life satisfaction than healthy controls. Cognitive behavioral therapy (CBT) and physical exercise have been shown to be cost-effective interventions for alleviating cancer-related menopause symptoms. Recently, an internet-based CBT intervention showed promising results for the treatment of menopausal symptoms in breast cancer survivors. Unless contraindicated, estrogen-containing hormone therapy should be initiated and continued until the estimated age of natural menopause. Hormone treatment improves the physical symptoms of women with POI, including vasomotor symptoms, vaginal dryness, and dyspareunia, and preserves BMD and cardiovascular health, but these hormonal treatments have a limited effect on QoL. Open communication, validation, and psychological interventions play a role in improving overall QoL.

An understanding of the patient’s values and attitudes toward menopause will guide culturally competent, whole-woman healthcare. Compared with 71% of oncologists, only 15% of primary care physicians are aware of the risk of premature menopause following exposure to alkylating agents. This disparity in awareness of late effects of cancer treatments highlights the need for a multidisciplinary team comprising gynecologists, endocrinologists, primary care providers, psychologists, social workers, physical therapists, and nurses to provide comprehensive care to cancer survivors. A team-based approach will ensure that providers address all aspects and consequences of POI during follow-up visits.

References


Ratchfie MA, Lanham SA, Reid DM, Dawson AA. Bone mineral density (BMD) in patients with lymphoma: the effects of chemotherapy,


